BCDA PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

BCDA ▼ -2.50% at T+20d

SHORT call ✓ call won +2.50% · α vs SPY +10.36% · entry $1.20 → $1.17

Next anchor: T+60d in 8d

Last close $0.9200 (close Jun 8) · +23.33% from $1.20 entry (call sign-flipped)

Entry anchored
Mar 24, 03:55 PM ET
via Databento tick

T+1d

-1.67%

call +1.67% · α -0.10%

$1.18

settled 3mo ago

T+5d

-3.33%

call +3.33% · α +3.09%

$1.16

settled 2mo ago

T+20d

-2.50%

call +2.50% · α +10.36%

$1.17

settled 7w ago

T+60d

—

call — · α —

—

in 8d

Price Chart

Loading chart...

Executive Summary

BioCardia reported its 2025 financial results, showing no revenue and a net loss of $8.2 million, with cash of $2.5 million. The company highlighted clinical progress in its CardiAMP and CardiALLO programs, including positive echocardiography data in heart failure and upcoming regulatory milestones with the FDA and PMDA, but continues to operate at a loss with minimal financial resources.

Key Financial Metrics

Revenue

$0.00

-100.0% YoY

EPS

$-1.23

Actionable Insight

Monitor upcoming FDA and PMDA interactions in Q2 2026 as potential catalysts, but be cautious due to lack of revenue, sustained losses, and limited cash runway that may necessitate dilutive financing.

Key Facts

No revenue in 2025 vs. $58,000 in 2024
Net loss increased to $8.2 million in 2025 from $7.9 million in 2024
Cash and cash equivalents totaled $2.5 million at year-end 2025
R&D expenses rose to $5.0 million, SG&A fell to $3.3 million
Positive blinded core lab data from CardiAMP HF trial showed reduced pathological remodeling in prespecified subgroup (p=0.02 and p=0.01)
FDA accepted Helix catheter Pre-Submission; meeting scheduled in Q2 2026
PMDA granted preliminary consultation on CardiAMP approval in Japan
Company plans Q-Sub filing with FDA for CardiAMP approval based on elevated biomarker subgroup

Financial Impact

Increased net loss of $8.2 million on zero revenue, with only $2.5 million cash remaining

revenuenet losscash

Risk Factors

Very low cash balance ($2.5M) relative to annual operating burn (~$7.4M)
No revenue and increasing net losses raise going concern risks
Clinical development progress does not offset deteriorating financial fundamentals
Potential for near-term dilution or failure to secure funding

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3261730

15 reports for BCDA

T+1T+5T+20T+60

29% Hit rate 2 of 7 directional calls best @ T+20▲ +10.08%Apr 15, 2026

Filters

Reports for BCDA — sortable, filterable
	Type				Now
Jun 8, 2026 1d ago	8-K BEARISH ★ 6/10	$0.8800 awaiting T+5	awaiting T+5	—	$0.9200 (−4.55%)
Jun 8, 2026 1d ago	Press Release BEARISH ★ 7/10	$0.8800 awaiting T+5	awaiting T+5	—	$0.9200 (−4.55%)
Jun 5, 2026 4d ago	8-K BULLISH ★ 6/10	$1.20 awaiting T+5	awaiting T+5	—	$0.9200 (−23.33%)
May 28, 2026 12d ago	8-K BULLISH ★ 7/10	$0.9200 $0.8700	▼ −5.43%	▼ −5.39%	$0.9200 (+0.00%)
May 15, 2026 25d ago	8-K MIXED ★ 6/10	$1.01 $0.9600	▼ −4.95%	▼ −5.91%	$0.9200 (−8.91%)
May 15, 2026 25d ago	Press Release MIXED ★ 6/10	$1.01 $0.9600	▼ −4.95%	▼ −5.91%	$0.9200 (−8.91%)
May 11, 2026 29d ago	Press Release NEUTRAL ★ 2/10	$1.12 $0.9000	▼ −19.64%	▼ −19.72%	$0.9200 (−17.86%)
May 8, 2026 4w ago	8-K BULLISH ★ 6/10	$1.11 $1.09	▼ −1.80%	▼ −3.27%	$0.9200 (−17.12%)
Apr 28, 2026 6w ago	8-K NEUTRAL ★ 2/10	$1.14 $1.13	▼ −0.88%	▼ −2.57%	$0.9200 (−19.30%)
Apr 20, 2026 7w ago	Press Release BULLISH ★ 8/10	$1.25 $1.16	▼ −7.20%	▼ −8.11%	$0.9200 (−26.40%)

US Market Status

Market Closed — Opens in 7h 22m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access